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Cell division involves a cyclical biochemical process composed of several step-wise reactions that have to occur once per cell cycle.
Dysregulation of cell division is a hallmark of all cancers. Genetic and epigenetic mechanisms frequently result in deranged expression
and/or activity of cell-cycle proteins including the cyclins, cyclin-dependent kinases (Cdks), Cdk inhibitors and checkpoint control
proteins. The critical nature of these proteins in cell cycling raises hope that targeting them may result in selective cytotoxicity and
valuable anticancer activity.
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STRATEGIES FOR TARGETING THE CELL CYCLE
Dysregulation of the cell cycle is a hallmark of malignancy
(Table 1). Many different strategies for targeting the cell cycle have
been described. Attention has focused primarily on targeting
mitosis (by targeting tubulin and more recently mitotic kinases
including KSP/Eg5, Polo-like kinase 1 and Aurora kinases) as well
as chemical inhibitors of cyclin-dependent kinase (Cdk) catalytic
activity. Other potential strategies include therapeutics that can
inhibit the interaction between cyclins and Cdks; decrease cyclin
expression; promote the degradation of cyclins by increasing their
phosphorylation; and restore endogenous Cdk inhibitor function.
Other possibilities include the inhibition of the ‘noncycling’ cyclin-
activating kinase complex of Cdk7/cyclin H, and the indirect
targeting of the late G2 to M checkpoint by inhibiting CDC25 or by
activating WEE1 or MYT1. This review will, however, focus on the
chemical Cdk inhibitors evaluated in clinical trials to date and will
highlight the main trial results reported to date.
PHARMACOLOGIC CDK INHIBITORS
Considerable progress has been made in the identification of
pharmacologic agents targeting the Cdks (Senderowicz, 2003). The
first generation of Cdk inhibitors lacked specificity, with
flavopiridol, staurosporine and its analogue UCN-01 and E7070
being nonselective inhibitors of not only Cdks but many other
targets. Second-generation inhibitors are more selective, with
many of these compounds specifically developed to target selected
Cdks (Table 2).
Flavopiridol
Flavopiridol (Alvocidibt) has several mechanisms of anticancer
activity (Senderowicz and Sausville, 2000) and is a broad-spectrum
Cdk inhibitor targeting Cdks 1, 2, 4, 6 and 7, interacting with the
adenosine triphosphate (ATP) binding site. Flavopiridol also
inhibits the Cdk9/cyclin T complex, broadly repressing transcrip-
tion and decreasing cyclin D1 mRNA expression (Carlson et al,
1999). It induces cell-cycle arrest in G1 and is cytotoxic to cells
undergoing DNA synthesis. It also inhibits other kinases including
PKC and PKA at higher concentrations, inducing apoptosis, (Patel
et al, 1998) and is active in many xenograft models.
The first Phase I trial of flavopiridol utilised a 72-h continuous
infusion every 2 weeks, a schedule supported by preclinical models
(Senderowicz et al, 1998). The maximum-tolerated dose (MTD)
achieved in this clinical trial was 50mgm
2day
 1, the initial dose-
limiting toxicity being secretory diarrhoea. The MTD with
antidiarrhoeal prophylaxis was 78mgm
2day
 1 (Kahn et al, 2001;
Messmann et al, 2003) The achieved plasma levels were sufficient
for Cdk inhibition (200–400nM), with one partial response in
renal cell cancer and minor responses in renal, colorectal
carcinomas and non-Hodgkin’s lymphoma.
This 72-h schedule was subsequently investigated in further
Phase I and Phase II trials in patients with mantle cell lymphoma,
renal cancer, melanoma, gastric cancer, non-small-cell lung
cancer (NSCLC) and colorectal cancers (Bennett et al, 1999;
Stadler et al, 2000; Schwartz et al, 2001; Shapiro et al, 2001; Lin
et al, 2002; Thomas et al, 2002). An unusually high incidence of
arterial and venous thromboembolic events was documented in
the majority of these trials, including deep venous thrombosis,
pulmonary thromboembolism, myocardial infarction and tran-
sient neurological ischaemic events. This serious drug-related
toxicity was not appreciated in the initial studies but was
reported in more than 30% of patients in later trials and is of
unknown aetiology.
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www.bjcancer.comA study of flavopiridol administered as a 1-h infusion was then
pursued supported by data indicating that higher plasma
concentrations than those achieved in the 72-h infusion studies
were required to induce apoptosis (Arguello et al, 1998; Tan et al,
2002). Initially, a 1-h infusion administered for 5 days every 3
weeks was investigated. The recommended Phase II dose for this
schedule was 37.5mgm
2day
 1, with grade 4 neutropenia and
grade 3 fatigue being dose limiting. The three- and one-day
schedules administered every 3 weeks were also evaluated with the
aim of further increasing peak serum levels of drug. Grade 4
neutropenia was also dose limiting in these studies, with the
recommended Phase II dose of these schedules being
50mgm
2day
 1 and 62.5mgm
 2, respectively. The peak plasma
concentrations, however, remained lower than the concentrations
required in preclinical studies to induce apoptosis (5–7mmoll
 1),
with no objective tumour responses being observed. Phase II
studies of flavopiridol administered by 1-h infusion daily for 3
days every 3 weeks have been reported. No responses were
observed in advanced melanoma (Burdette-Radoux et al, 2002);
however, in patients with advanced mantle cell lymphoma, three
responses out of 28 evaluable patients (11%) were reported, with
20 patients having stable disease (71%) for a median duration of
3.4 months (Kouroukis et al, 2003).
An alternative administration schedule has been recently
evaluated for flavopiridol in patients with chronic lymphatic
leukaemia. Previous Phase I/II studies had shown that, while
flavopiridol induces apoptosis in CLL cells in a p53-independent
manner in vitro, the drug is inactive using a 24- to 72-h CIVI
schedule. Based on pharmacokinetic modelling data demonstrat-
ing high drug binding to human plasma proteins, an optimised
dosing schedule of 30-min i.v. bolus (IVB) followed by 4-h CIVI
has been pursued. This alternative schedule has demonstrated
promising activity including flavopiridol-induced tumour lysis
syndrome, suggesting that this agent may warrant further
evaluation using this novel schedule (Lin et al, 2004).
The use of flavopiridol in combination studies has also been
pursued (Bible and Kaufmann, 1997; Motwani et al, 2001).
Treatment scheduling appears to be important in ensuring that
flavopiridol augments the effects of other agents (Schwartz et al,
2002; Wittmann et al, 2003).
UCN-01
The second chemical Cdk inhibitor to be evaluated was UCN-01
(7-hydroxystaurosporine) (Senderowicz and Sausville, 2000),
which also has several mechanisms of action including Cdk1
(cdc2) and Cdk2 inhibition (IC50 of 300–600nM). UCN-01 causes
cell-cycle arrest and apoptosis at concentrations above 100nM
(Akiyama et al, 1997), abrogating the G2 checkpoint in response
to DNA damage and promoting the induction of p53-independent
apoptosis by inhibiting Chk1 and Chk2 (IC50 for both
approximately 10–30nM). (Wang et al, 1996; Busby et al, 2000;
Yu et al, 2002). UCN-01 also abrogates S-phase arrest in CHO
cells treated with cisplatin, promoting the induction of apoptosis
(Bunch and Eastman, 1997), and may target Akt signalling by
inhibiting PDK1 (IC50¼33nM) (Sato et al, 2002). Frequent dosing
is required to optimise the antitumour activity of UCN-01
(Sausville et al, 1998), and 72h of drug exposure is required to
achieve growth inhibition. A Phase I trial of UCN-01 adminis-
tered as a 72-h continuous infusion every 2 weeks to patients
with advanced malignancy revealed long elimination half-lives
due to high-affinity binding of UCN-01 to a1-acid glycoprotein in
human plasma (Fuse et al, 1998; Sausville et al, 2001). This
schedule was therefore changed to a 72-h continuous infusion
administered every 4 weeks, with a recommended dose of
42.5mgm
2day
 1. Dose-limiting toxicities at 53mgm
 2 included
hyperglycaemia, pulmonary toxicity with hypoxaemia, emesis and
hypotension. The basis for the pulmonary toxicity was unclear
but did not involve altered cardiac motility or pulmonary
thromboembolism, being associated with small, transient, pleural
effusions. Hyperglycaemia occurred at all dose levels. Analysis of
immunoreactive C peptide levels suggested that this was related
to peripheral tissue insulin resistance rather than a decrease in
insulin secretion. Pharmacokinetic analysis revealed a terminal
half-life of 588h, with mean drug plasma concentrations in the
micromolar range. Analysis of free salivary levels of UCN-01
showed drug levels of approximately 100nm, which is sufficient
to affect cell-cycle parameters in vitro. A partial response of 6
months duration was observed in patient with melanoma, and a
complete response, sustained for over 38 months in a patient
with anaplastic large-cell lymphoma.
E7070
E7070 is a chloroindolyl sulphonamide that induces G1/S cell cycle
arrest at low nanomolar concentrations, inhibiting Cdk2/cyclin E,
downregulating cyclin H, upregulating p53 and p21, and inducing
Table 1 (a) Deregulated cyclins and Cdk’s and associated tumours and
(b) deregulated endogenous Cdk inhibitors and associated tumours
Target Oncogenic changes Associated tumours
(a)
Cyclin D1 Gene amplification 40–80% Breast carcinoma
Overexpression 70% Familial polyposis
Translocation 50% B-cell lymphoma
50% NSCLC
35% Head and neck carcinoma
25–50% Oesophageal carcinoma
25% Bladder carcinoma
Cyclin E Gene amplification 90% Colorectal carcinoma
Overexpression 30–80% Breast carcinoma
70% Prostate carcinoma
18% Ovarian carcinoma
Gastric carcinoma
Cervical carcinoma
Cyclin E2 Overexpression Breast carcinoma
Small-cell lung carcinoma
Cervical carcinoma
Cyclin B1 Overexpression 90% Colorectal carcinoma
Cyclin A Amplification or overexpression Hepatocellular carcinoma
CDK2 Overexpression Colorectal carcinoma
CDK4 Amplification Sarcomas, gliomas
(b)
p16
INK4a Mutation (5% of human cancers) Pancreatic cancer
Deletion (14% of human cancers) Melanoma
Epigenetic (19% of human cancers) Gliomas
Bladder cancer
Head and neck cancer
NSCLC
Lymphoma/leukaemia
p21
cip 1/
waf 1
Mutation/deletion rare Oral (rare mutations)
Downregulation rare Oesophageal (rare mutations)
Intracellular mislocalis ation? Breast (rare mutations)
p27
kip 1 Mutations/deletions rare Breast
a
Downregulation (increased
degradation)
a
Colon
a
Prostate
a
NSCLC¼non-small-cell lung cancer.
aIncreased degradation.
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drug exposures (Ozawa et al, 2001). E7070 has a broad spectrum of
in vitro and in vivo preclinical antitumour activity, inducing
regression of established tumours. This efficacy is schedule
dependent, with a daily-for-8-days schedule being more efficacious
than 4- and 1-day schedules.
A number of Phase I trials of this agent have been performed
investigating different dosing regimens. When given daily by
intravenous infusion for 5 days every 3 weeks, the DLTs
consisted of neutropenia, thrombocytopenia, diarrhoea and
stomatitis, with a recommended Phase II dose of
130mgm
2day
 1. One partial response was seen in a patient with
heavily pretreated breast cancer (Punt et al, 2001). A second trial
investigated an alternative schedule – a 1-h infusion administered
every 3 weeks (Raymond et al, 2002). Toxicities were similar to
the 5-day regimen and comprised myelosuppression, acne-like
skin rash, alopecia, mucositis, conjunctivitis, hypoglycaemia,
nausea and fatigue. Recommended doses were 700mgm
 2 for
the heavily pretreated group and 800mgm
 2 for the lightly
pretreated group. No partial responses were observed. A weekly
1-h infusion schedule for 4 consecutive weeks and a continuous
120-h infusion have also been evaluated with similar toxicities
being observed. The recommended doses for the weekly and
continuous infusion schedules were 400 and 96mgm
 2, respec-
tively. Pharmacokinetic studies indicate that the clearance and
volume of distribution at steady state of E7070 decrease with
increasing dose.
Phase II single-agent studies are under way in a number of
different tumour types investigating the once-every-3-weeks and
daily-for-5-days schedules. In patients with fluorouracil refractory
colorectal cancer, two of 21 patients receiving the once-every-4-
weeks schedule, and two of 23 patients receiving the daily-for-5-
days schedule, had objective responses, with 10 and 13%
of patients, respectively, having stable disease at 6 months
(Mainwaring et al, 2002). In a Phase II study of patients with
NSCLC, who had previously received one chemotherapy regimen,
only one of 44 patients had an objective response (Talbot et al,
2002). No objective responses were observed in patients with
metastatic melanoma receiving a dose of 700mgm
 2 for over 1h
every 3 weeks (Aamdal et al, 2002).
R-Roscovitine (CYC202)
The purine analogue R-roscovitine (CYC202) is a highly selective,
orally bioavailable, small molecule inhibitor of several Cdks
competing with their ATP binding sites: it is a relatively potent
inhibitor of human Cdk2/cyclin E, Cdk7/cyclin H, Cdk9/cyclin T1
with IC50 of 0.1, 0.5 and 0.8mM, respectively (Meijer et al, 1997),
but inhibits Cdk4/cyclin D1 with an IC50 of 14.2mM. It has an
average IC50 against the NCI cell-line panel of 16mM. It also blocks
the degradation of p53 through the inhibition of MDM2 expression
(Lu et al, 2001). CYC202 induces G1 and G2/M arrest and cell death
from all compartments of the cell cycle (Schutte et al, 1997; McClue
et al, 2002). The antitumour efficacy of CYC202 has also been
tested in a panel of human tumour xenografts (McClue et al, 2002).
Continuous exposure to CYC202 at dosages ranging from 0.3 to
100mM demonstrated dose-dependent antitumour activity.
Recent molecular pharmacology studies have shown that
treatment of colorectal cancer cells with CYC202 results in a
decrease in pRb phosphorylation (serines 780, 608, 807, 811 and
Thr-821), indicative of direct Cdk2 inhibition (Whittaker et al,
2004). In addition, CYC202 causes a downregulation of various
cyclins, including cyclin D1; this is likely to lead to a secondary
inhibition of various cyclins, which would explain the reduced
phosphorylation at multiple sites on RB that is seen at later time
points.
CYC202 has been evaluated in Phase I clinical trials. Two such
trials have recently been reported. In the first trial, CYC202 was
administered orally, twice daily for 7 days out of every 21. In all, 19
patients were treated for a total of 36 cycles of CYC202. At 800mg
BD, DLTs comprising grade 3 skin rash and grade 4 hypokalaemia
were observed. Other toxicities seen included reversible renal
impairment, mild reversible transaminitis and emesis. MAG-3
studies indicated that the renal impairment was related to altered
renal blood flow. No evidence of renal tubular damage was
detected. The aetiology of these renal changes is unknown but
could be related to the effects of CYC202 on adenosine receptors.
The pharmacokinetics of the compound were dose proportional,
with CYC202 being widely distributed (720.8l, 95% CI 384.9–
1056.8) and rapidly cleared (142.6l/h, 95% CI 80.5–204.9) with a
mean terminal elimination half-life of 4.02h (95% CI 2.8–5.2).
Table 2 Chemical Cdk inhibitors and their targets
N
S H
N
O
S
N
O
N
N N
H
N
N
HO
HN
NH
O
N
OH
HO
O
Cl
H
OH
CH3
Cdk Inhibitors in the Clinic
BMS 387032
Cdk1/B IC50 = 0.481µM
Cdk2/E IC50 = 0.048 µM
Cdk4/D IC50 = 0.925 µM
Flavopiridol
Cdk1/B IC50= 0.03 µM
Cdk2/E IC50= 0.17 µM
Cdk4/D IC50= 0.10 µM
Cdk9/T IC50 <  0.010  µM
a
R-Roscovitine (CYC-202)
Cdk1/B IC50 = 2.69 µM
Cdk2/E IC50 = 0.10 µM
Cdk4/D IC50 = 14.21 µM
Cdk7/H IC50  = 0.5 µM
a
Cdk9/T1 IC50 = 0.8 µM
a
UCN01
Cdk1/B IC50 =  0.3  µM
Cdk2/E IC50 =  0.3  µM
PKC IC50 = 0.03 µM
Chk1 IC50 = 0.011 µM
Chk2 IC50 = 1.04 µM
NH o
o
NN
Me
OMe
NHMe
OH
aIncreased degradation downregulate transcription, for example, kcyclin D1 expression.
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have yet been seen (Benson et al, 2003; White et al, 2004).
In the second trial, a twice-daily-for-5-days schedule, adminis-
tered every 3 weeks was evaluated. The maximum twice-daily dose
achieved was 1600mg BD with a recommended dose of 1250mg
BD. Toxicities reported have included grade 4 emesis, grade 3
asthenia and skin rash. No objective responses were seen but stable
disease was recorded in three out of 29 patients treated. (Pierga
et al, 2003) Exploration of a 10-day schedule is now under way.
BMS-387032
High-throughput screening followed by lead optimisation has
resulted in the identification of the 2-aminothiazole BMS-387032
as a potent, selective and competitive small molecule inhibitor of
the Cdk2/cyclin E complex, with an IC50 of 48nM. The 2-
aminothiazoles have been reported to be 10- and 30-fold more
potent against Cdk2 than Cdk1 and Cdk4, and three to five orders
of magnitude less potent against all other tested non-Cdk kinases.
The X-ray crystal structure of this compound with Cdk2 has been
reported, and has revealed the mechanisms by which this
compound interacts with the Cdk2 ATP binding site (Misra et al,
2004). In vitro, BMS-387032 inhibits Cdk2 phosphorylation in the
A2780 ovarian carcinoma cell line, inhibiting the phosphorylation
of downstream targets of Cdk2 including pRb, histone H1 and
DNA polymerase-a.
The compound displays potent in vitro cytotoxicity against the
A2780 cell line with an IC50 of 50nM, and is active against a broad
array of cell lines. In vivo studies have confirmed oral bioavail-
ability and activity against a variety of cell lines, including P388
murine leukaemia, A2780 ovarian and A431 human squamous cell
carcinoma. Combination studies indicate that BMS-387032 is
synergistic with cisplatin in SV-1 colon carcinoma cells, this
synergy being dependent on the drug sequence (Lane et al, 2003).
Phase I clinical trials with BMS-387032 are ongoing utilising
different schedules (Jones et al, 2003; McCormick et al, 2003;
Shapiro et al, 2003).
PHARMACODYNAMIC STUDIES
As with other molecularly targeted therapeutics under investiga-
tion, the clinical development of the Cdk inhibitors in early trials
requires the study of their biological effects in tumour cells
acquired through serial tumour biopsies. These studies are
required to select optimal biological dosing and schedule, and
identify the patient population most likely to benefit from these
agents. Potential pharmacodynamic parameters under investiga-
tion include the inhibition of pRb phosphorylation; the depletion
of cyclins and Cdks; increases in Cdk inhibitor protein expression;
and the suppression of mdm2 expression and induction of p53
expression. Pharmacodynamic studies have been reported for
flavopiridol (Lam et al, 2001) and CYC202 (Whittaker et al, 2004).
More recent studies indicate that
18F-labelled 30-deoxy-
30fluorothymidine may be a useful imaging modality for the
selective Cdk2 inhibitor BMS-387032 (Fischman et al, 2004). These
translational studies are critically important in the optimal
development of these agents.
CONCLUDING REMARKS
Significant progress has been made in the clinical targeting of the
Cdks. Newer and more specific Cdk inhibitors are envisioned to
result in decreased toxicity and more selective cytotoxicity.
Increased specificity may not, however, spare noncycling cells
since recent data have implicated the Cdks 5, 7, 8 and 9 in cellular
functions that do not involve the cell cycle. Cdks 7, 8 and 9 have
been reported to regulate RNA transcription through the
phosphorylation of RNA polymerase II, while Cdk5 has been
shown to be involved in regulating insulin secretion, synaptic
vesicle recycling, neuronal survival and tau (microtubule asso-
ciated protein) phosphorylation and aggregation (Sausville, 2002).
These findings may explain why hyperglycaemia has been
observed with many chemical Cdk inhibitors. The RNA polymer-
ase II regulatory activity of Cdk 7, 8 and 9 may, however, enhance
the antitumour effect of these agents, and it has indeed been
suggested that the anticancer activity of flavopiridol may be in part
related to the inhibition of RNA transcription. It remains to date
unclear whether the inhibition of Cdk 7, 8 and 9 activity is
desirable for an anticancer agent, or whether the toxicity
associated with inhibiting these noncycling Cdks will substantially
decrease cytotoxic selectivity and the therapeutic index.
Overall, these data suggest that highly selective small molecule
inhibitors of specific Cdks may be preferable in order to decrease
toxicity. Generating this specificity, however, not only remains a
significant challenge to chemists but may also decrease anticancer
efficacy in view of the inherent functional redundancy of this
family of kinases. A broader-spectrum inhibitor that can, for
example, selectively inhibit Cdk1, Cdk2, Cdk4 and Cdk6 at low
nanomolar IC50 concentrations may therefore be preferable. The
recent observations that selectively inhibiting Cdk2 in certain cell
lines is not sufficient for antitumour activity would support this
view (Tetsu and McCormick, 2003), as would the demonstration
that the Cdk2 knockout mouse shows no major abnormalities and
in particular no effects on proliferation (Ortega et al, 2003). The
high sequence homology of the ATP binding sites of these and the
noncycling kinases Cdk 5, 7, 8 and 9, as well as that of glycogen
synthase kinase-3b and that of the adenosine receptors makes this
a difficult task. However, much has already been achieved and
while many questions need to be answered we are moving closer to
the Holy Grail: the development of compounds selectively
cytotoxic to tumour cells, yet sparing normal cells.
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